vs
基华物流（CEVA）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
基华物流的季度营收约是STANDARD BIOTOOLS INC.的1.6倍（$31.3M vs $19.6M），基华物流净利率更高（-3.5% vs -177.4%，领先173.9%），基华物流同比增速更快（7.1% vs -11.5%），基华物流自由现金流更多（$7.2M vs $-23.1M），过去两年基华物流的营收复合增速更高（19.1% vs -12.2%）
赛物流是一家全球物流与供应链企业，提供货运管理以及合约物流服务，2019年被达飞海运集团收购。收购完成后，达飞集团陆续将英格迈微商务生命周期服务、GEFCO等多家物流运输企业并入赛物流，助力其业务发展与规模扩张。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
CEVA vs LAB — 直观对比
营收规模更大
CEVA
是对方的1.6倍
$19.6M
营收增速更快
CEVA
高出18.5%
-11.5%
净利率更高
CEVA
高出173.9%
-177.4%
自由现金流更多
CEVA
多$30.3M
$-23.1M
两年增速更快
CEVA
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $31.3M | $19.6M |
| 净利润 | $-1.1M | $-34.7M |
| 毛利率 | 88.1% | 48.5% |
| 营业利润率 | -1.3% | -168.5% |
| 净利率 | -3.5% | -177.4% |
| 营收同比 | 7.1% | -11.5% |
| 净利润同比 | 36.8% | -28.8% |
| 每股收益（稀释后） | — | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CEVALAB
| Q4 25 | $31.3M | — | ||
| Q3 25 | $28.4M | $19.6M | ||
| Q2 25 | $25.7M | $21.8M | ||
| Q1 25 | $24.2M | $40.8M | ||
| Q4 24 | $29.2M | — | ||
| Q3 24 | $27.2M | $22.1M | ||
| Q2 24 | $28.4M | $22.5M | ||
| Q1 24 | $22.1M | $45.5M |
净利润CEVALAB
| Q4 25 | $-1.1M | — | ||
| Q3 25 | $-2.5M | $-34.7M | ||
| Q2 25 | $-3.7M | $-33.5M | ||
| Q1 25 | $-3.3M | $-26.0M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-1.3M | $-26.9M | ||
| Q2 24 | $-291.0K | $-45.7M | ||
| Q1 24 | $-5.4M | $-32.2M |
毛利率CEVALAB
| Q4 25 | 88.1% | — | ||
| Q3 25 | 88.0% | 48.5% | ||
| Q2 25 | 86.2% | 48.8% | ||
| Q1 25 | 85.6% | 48.4% | ||
| Q4 24 | 88.5% | — | ||
| Q3 24 | 85.4% | 54.9% | ||
| Q2 24 | 89.7% | 46.1% | ||
| Q1 24 | 88.7% | 53.1% |
营业利润率CEVALAB
| Q4 25 | -1.3% | — | ||
| Q3 25 | -7.3% | -168.5% | ||
| Q2 25 | -17.5% | -118.1% | ||
| Q1 25 | -18.1% | -80.8% | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | -9.6% | -120.9% | ||
| Q2 24 | -0.1% | -134.5% | ||
| Q1 24 | -22.5% | -132.2% |
净利率CEVALAB
| Q4 25 | -3.5% | — | ||
| Q3 25 | -8.8% | -177.4% | ||
| Q2 25 | -14.4% | -153.7% | ||
| Q1 25 | -13.7% | -63.8% | ||
| Q4 24 | -5.9% | — | ||
| Q3 24 | -4.8% | -122.0% | ||
| Q2 24 | -1.0% | -203.3% | ||
| Q1 24 | -24.7% | -70.6% |
每股收益（稀释后）CEVALAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.09 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.12 | ||
| Q1 24 | — | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $40.6M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $336.5M | $399.7M |
| 总资产 | $388.3M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CEVALAB
| Q4 25 | $40.6M | — | ||
| Q3 25 | $17.3M | $129.4M | ||
| Q2 25 | $29.1M | $158.6M | ||
| Q1 25 | $18.8M | $150.9M | ||
| Q4 24 | $18.8M | — | ||
| Q3 24 | $13.2M | $210.6M | ||
| Q2 24 | $25.0M | $269.8M | ||
| Q1 24 | $21.6M | $287.1M |
总债务CEVALAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益CEVALAB
| Q4 25 | $336.5M | — | ||
| Q3 25 | $268.7M | $399.7M | ||
| Q2 25 | $265.9M | $424.5M | ||
| Q1 25 | $269.1M | $454.6M | ||
| Q4 24 | $266.6M | — | ||
| Q3 24 | $265.8M | $489.3M | ||
| Q2 24 | $263.8M | $510.3M | ||
| Q1 24 | $262.3M | $577.3M |
总资产CEVALAB
| Q4 25 | $388.3M | — | ||
| Q3 25 | $306.0M | $539.6M | ||
| Q2 25 | $302.8M | $557.0M | ||
| Q1 25 | $310.0M | $579.6M | ||
| Q4 24 | $308.9M | — | ||
| Q3 24 | $304.9M | $681.5M | ||
| Q2 24 | $300.4M | $708.7M | ||
| Q1 24 | $301.4M | $777.7M |
负债/权益比CEVALAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $8.7M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $7.2M | $-23.1M |
| 自由现金流率自由现金流/营收 | 23.1% | -118.1% |
| 资本支出强度资本支出/营收 | 4.8% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-6.3M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流CEVALAB
| Q4 25 | $8.7M | — | ||
| Q3 25 | $-5.9M | $-22.2M | ||
| Q2 25 | $1.2M | $-20.7M | ||
| Q1 25 | $-7.4M | $-30.3M | ||
| Q4 24 | $8.0M | — | ||
| Q3 24 | $399.0K | $-27.9M | ||
| Q2 24 | $2.4M | $-39.0M | ||
| Q1 24 | $-7.3M | $-62.5M |
自由现金流CEVALAB
| Q4 25 | $7.2M | — | ||
| Q3 25 | $-6.3M | $-23.1M | ||
| Q2 25 | $492.0K | $-22.6M | ||
| Q1 25 | $-7.7M | $-35.3M | ||
| Q4 24 | $7.0M | — | ||
| Q3 24 | $-15.0K | $-30.1M | ||
| Q2 24 | $1.8M | $-41.0M | ||
| Q1 24 | $-8.3M | $-63.3M |
自由现金流率CEVALAB
| Q4 25 | 23.1% | — | ||
| Q3 25 | -22.1% | -118.1% | ||
| Q2 25 | 1.9% | -103.6% | ||
| Q1 25 | -31.8% | -86.6% | ||
| Q4 24 | 24.0% | — | ||
| Q3 24 | -0.1% | -136.4% | ||
| Q2 24 | 6.2% | -182.2% | ||
| Q1 24 | -37.4% | -138.9% |
资本支出强度CEVALAB
| Q4 25 | 4.8% | — | ||
| Q3 25 | 1.5% | 4.5% | ||
| Q2 25 | 2.7% | 8.7% | ||
| Q1 25 | 1.3% | 12.4% | ||
| Q4 24 | 3.5% | — | ||
| Q3 24 | 1.5% | 10.2% | ||
| Q2 24 | 2.1% | 8.6% | ||
| Q1 24 | 4.1% | 1.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CEVA
| Transferred At Point In Time | $28.1M | 90% |
| Transferred Over Time | $3.2M | 10% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
